Bringing cell therapies for autoimmunity into the mainstream

Autoimmune patients have long been underserved by treatments that are blunt instruments. While repurposed oncology cell therapies hint at new avenues, they aren't optimized for the realities of today’s autoimmune patients. We’ve set out to change that via therapeutics optimized for safety and patient access.

The oncology cell therapy paradigm is not the answer in autoimmunity

While the feasibility of CAR-T therapy for autoimmune diseases has been underscored by the efficacy seen in early trials, there are significant limitations:

  • Patient Selection Dilemma: CAR-T's toxicity demands meticulous patient selection. It's a delicate balance: patients must be sufficiently ill to warrant this novel therapy but not so compromised that they are extra sensitive to potentially fatal adverse events like cytokine release syndrome (CRS) and Macrophage Activation Syndrome (MAS).

  • Accessibility Issues: The current reliance on autologous products restricts widespread patient access. Treatments are predominantly available only in elite medical institutions. To adequately serve high-risk lupus patients, it would require over 20 times the current commercial CAR-T doses.

  • Need for Lymphodepletion: Burdensome and toxic chemotherapy regimens are standard practice prior to cell therapy administration. In order to bring these therapies to significantly more patients, these protocols must be eliminated.

These challenges underscore the pressing need for a more universally applicable solution.

Our answer… Cell therapy efficacy in a drug-like package

Broad Accessibility

  • Off-the-shelf CAR-NK chassis

    • Leverage the 20+ year clinical safety record of NK cells

    • Unlike CAR-T, where drug kinetics can be highly variable, NK cells have a well-defined kinetic profile. They go in, do their job, and disappear

  • Avoiding lymphodepletion

    • Express engineered receptors to overcome lymphodepletion requirement

    • Massive increase in accessible patient population

Tailored Potency

  • Best-in-class NK-specific CARs

    • Eliminate autoreactive cells

    • Doubled potency window over legacy CARs

  • Switch Receptor Arrays

    • Tune potency for different patient subsets

    • Leverage multiple mechanisms of action to address heterogeneous diseases

How we approach cell therapy design differently

Accelerating cell therapy discovery with rapid prototyping and generative design

Drawing inspiration from agile engineering approaches, we’re designing cell therapies from building blocks, using pre-made components that can be combined in different ways to achieve complex design goals. We rapidly prototype and test thousands of cell designs in parallel to identify the most effective combinations of components for a given set of design goals. Executing these state-of-the-art synthetic biology approaches in primary immune cells has required multidisciplinary innovation in both molecular and cell engineering.

Tools: Switch Receptor Arrays

Switch receptors are powerful cell engineering components that give cells the ability to respond to environmental signals, even inhibitory ones, and convert those signals into activating or survival cues. Modulus has developed a platform for the discovery of novel switch receptors, which enables the precise control of CAR-T and CAR-NK cell activity in response to a switch ligand. This technology has the potential to improve the safety and efficacy of cell therapies by allowing for more precise control over their activation and targeting.

Tools: Best-in-class NK-specific CARs

Chimeric Antigen Receptors (CARs) are a type of engineered protein receptor that can be expressed on the surface of immune cells, particularly engineered T-cells and Natural Killer (NK) cells. CARs are designed to recognize specific antigens present on diseased cells and activate effector cells to target and destroy those cells. Modulus has developed a platform for discovery of custom CARs to enhance the persistence and cytotoxicity of T and NK cells. Our CAR-T and CAR-NK components are designed to enhance proliferation and cytotoxicity providing a deeper and more durable response against target cells.

See our recent preprint on Bioarxiv

Creative and experienced leaders in cell therapy, molecular engineering, autoimmunity, data science

  • Max Darnell, Ph.D.

    Co-Founder & CEO

    Read More

  • Bryce Daines, Ph.D.

    Co-Founder & CTO

    Read More

  • Nicole Costa

    Nicole Costa, M.S.

    VP Portfolio Strategy and TechOps

    Read More

  • Brian Belmont, Ph.D.

    Head of Discovery Platform

    Read More

  • Lan Guo, Ph.D.

    Head of Data Science

    Read More

  • Rebekah Turk

    Scientist

    Read More

  • Aye Chen

    Senior Scientist

    Read More

  • Nick Bogard, Ph.D.

    Principal Scientist

  • Natalia Giltiay, Ph.D.

    Natalia Giltiay, Ph.D.

    Senior Principal Scientist, Preclincial Development

  • Keith Eldon, MD

    Keith Elkon, MD

    Scientific Advisor

  • Alana Welm, Ph.D.

    Scientific Advisor

    Read More

  • Jon Graf

    Jon Graf, MD

    Scientific Advisor

  • Raphael Gottardo, Ph.D.

    Scientific Advisor

    Read More

  • Georg Seelig

    Georg Seelig, Ph.D.

    Scientific Advisor

Company Logo-03.jpg
Company Logo-01.jpg
Company Logo-02.jpg

Modulus is supported by top investment firms who share the company's vision for accelerating cell therapy innovation.